Treatment options beyond IFNα and NUCs for chronic HBV infection: Expectations for tomorrow

Journal of Viral Hepatitis

Volumn 21, Issue 11, 2014, Pages 753-761

  Baltayiannis, G ^a   Karayiannis, P ^b  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY OF NICOSIA   (Cyprus)

Author keywords

anti HBV drugs; antiviral treatment; cccDNA; HBV life cycle; inhibitors

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CIRCULAR DNA; CORE PROTEIN; CYCLOSPORIN A; CYCLOSPORIN B; DNA VACCINE; EZETIMIBE; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; NUCLEOSIDE DERIVATIVE; OXYSTEROL; PEGINTERFERON ALPHA; RIBONUCLEASE H; RNA DIRECTED DNA POLYMERASE; SODIUM BILE ACID COTRANSPORTER; SYNTHETIC DNA; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR AGONIST; VIRUS ANTIGEN; VIRUS MESSENGER RNA; VIRUS PROTEIN; ALPHA INTERFERON; ANTIVIRUS AGENT; NUCLEOTIDE;

ANTIBODY RESPONSE; ANTIGEN ANTIBODY COMPLEX; CD8+ T LYMPHOCYTE; CYTOPLASM; CYTOTOXIC T LYMPHOCYTE; DNA SYNTHESIS; DNA TRANSCRIPTION; GENE OVEREXPRESSION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOTHERAPY; LIFE CYCLE; LIVER CELL; LIVER HISTOLOGY; MINICHROMOSOME; MONOTHERAPY; NONHUMAN; NUCLEAR ENTRY; NUCLEAR PORE; OPEN READING FRAME; OUTCOME ASSESSMENT; REVERSE TRANSCRIPTION; REVIEW; RNA INTERFERENCE; RNA SEQUENCE; SEROCONVERSION; VIRAL LIFE CYCLE; VIRION; VIROGENESIS; VIRUS ATTACHMENT; VIRUS ENTRY; VIRUS GENOME; VIRUS NUCLEOCAPSID; VIRUS REPLICATION; VIRUS UNCOATING; DRUG DEVELOPMENT; HEPATITIS B, CHRONIC; ISOLATION AND PURIFICATION; PROCEDURES; TREATMENT OUTCOME; TRENDS;

ANTIVIRAL AGENTS; DRUG DISCOVERY; HEPATITIS B, CHRONIC; HUMANS; IMMUNOTHERAPY; INTERFERON-ALPHA; NUCLEOTIDES; TREATMENT OUTCOME;

EID: 84907980499     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12307     Document Type: Review

References (68)

1. Lee WM,. Hepatitis B virus infection. N Engl J Med 1997; 337: 1733-1745.
2. Asselah T, Marcellin P,. Long-term results of treatment with nucleoside and nucleotide analogues (entecavir and tenofovir) for chronic hepatitis B. Clin Liver Dis 2013; 17: 445-450.
3. Lok ASF, McMahon BJ,. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 1-36.
4. Buti M, Cornberg M, Mutimer D, Pol S, Raimondo G,. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-185.
5. Seeger C, Mason WS,. Hepatitis B virus biology. Microbiol Mol Biol Rev 2000; 64: 51-68.
6. Ganem D, Schneider RJ,. Hepadnaviridae: the viruses and their replication. In:, Knipe DM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE, eds. Fields Virology, 4th edn. Philadelphia: Lippincott Williams & Wilkins, 2001: 2923-2969.
7. Ganem D, Prince AM,. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 2004; 350: 1118-1129.
8. Yan H, Zhong G, Xu G, et al,. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife 2012; 1: e00049.
9. Neurath AR, Kent SB, Strick N, Parker K,. Identification and chemical synthesis of a host cell receptor binding site on hepatitis B virus. Cell 1986; 46: 429-436.
10. Neurath AR, Seto B, Strick N,. Antibodies to synthetic peptides from the preS1 region of the hepatitis B virus (HBV) envelope (env) protein are virus-neutralizing and protective. Vaccine 1989; 7: 234-236.
11. Nkongolo S, Ni Y, Lempp FA, et al,. Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor. J Hepatol 2014; 60: 723-731.
12. Watashi K, Sluder A, Daito T, et al,. Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP). Hepatology 2014; 59: 1726-1737.
13. Iwamoto M, Watashi K, Tsukuda S, et al,. Evaluation and identification of hepatitis B virus entry inhibitors using HepG2 cells overexpressing a membrane transporter NTCP. Biochem Biophys Res Commun 2014; 443: 808-813.
14. Gripon P, Cannie I, Urban S,. Efficient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein. J Virol 2005; 79: 1613-1622.
15. Volz T, Allweiss L, Ben MBarek M, et al,. The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. J Hepatol 2013; 58: 861-867.
16. Macovei A, Petrareanu C, Lazar C, Florian P, Branza-Nichita N,. Regulation of hepatitis B virus infection by Rab5, Rab7, and the endolysosomal compartment. J Virol 2013; 87 (11): 6415-6427.
17. Sainz B, Barretto N, Martin DN, et al,. Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. Nat Med 2012; 18: 281-285.
18. Lucifora J, Esser K, Protzer U,. Ezetimibe blocks hepatitis B virus infection after virus uptake into hepatocytes. Antiviral Res 2013; 97: 195-197.
19. Nguyen DH, Ludgate L, Hu J,. J hepatitis B virus-cell interactions and pathogenesis. J Cell Physiol 2008; 216: 289-294.
20. Tuttleman JS, Pourcel C, Summers J,. Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells. Cell 1986; 47: 451-460.
21. Lucifora J, Xia Y, Reisinger F, Zhang K, Stadler D, et al,. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science 2014; 343 (6176): 1221-1228.
22. Pollicino T, Belloni L, Raffa G, et al,. Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones. Gastroenterology 2006; 130: 823-837.
23. Belloni L, Pollicino T, Cimino L, Raffa G, Raimondo G, Levrero M,. Nuclear HBx binds in vivo on the HBV minichromosome, modifies the epigenetic regulation of ccc-DNA function and potentiates HBV replication. J Hepatol 2008; 48: s25.
24. Palumbo TG, Belloni L, Pediconi N, Levrero M,. Targeting the cccDNA by epigenetic drugs inhibits HBV transcription and replication. Hepatology 2013; 58 (S1): 650A.
25. Kramvis A, Kew MC,. Structure and function of the encapsidation signal of hepadnaviridae. J Viral Hepat 1998; 5: 357-367.
26. Summers J, Mason WS,. Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate. Cell 1982; 29: 403-415.
27. Wagner RW,. Gene inhibition using antisense oligodeoxynucleotides. Nature 1994; 372: 333-335.
28. von Weizsacker F, Blum HE, Wands JR,. Cleavage of hepatitis B virus RNA by three ribozymes transcribed from a single DNA template. Biochem Biophys Res Commun 1992; 189: 743-748.
29. Beck J, Nassal M,. Efficient hammerhead ribozyme-mediated cleavage of the structured hepatitis B virus encapsidation signal in vitro and in cell extracts, but not in intact cells. Nucleic Acids Res 1995; 23: 4954-4962.
30. http://www.arrowheadresearch.com/programs/ARC-520 (accessed 02 June 2014).
31. Karayiannis P,. Serum hepatitis B surface antigen levels and their utility as a predictor of sustained virological response after antiviral treatment. Hepat Mon 2012; 12: 420-422.
32. Wu GY, Zheng XJ, Yin CC, et al,. Inhibition of hepatitis B virus replication by Bay 41-4109 and its association with nucleocapsid disassembly. J Chemother 2008; 20: 458-467.
33. Wang XY, Wei ZM, Wu GY, et al,. In vitro inhibition of HBV replication by a novel compound, GLS4, and its efficacy against adefovir-dipivoxil-resistant HBV mutations. Antivir Ther 2012; 17: 793-803.
34. http://www.drugdevelopment-technology.com/news/newsnovira-initiates-phase-ia-trial-of-nvr-1221-to-treat-chronic-hepatitis-b-infection-258446331.html (accessed 27 June 2014).
35. Weber O, Schlemmer KH, Hartmann E, et al,. Inhibition of human hepatitis B virus (HBV) by a novel non-nucleosidic compound in a transgenic mouse model. Antiviral Res 2002; 54: 69-78.
36. Brezillon N, Brunelle MN, Massinet H, et al,. Antiviral activity of Bay 41-4109 on hepatitis B virus in humanized Alb-uPA/SCID mice. PLoS One 2011; 6 (12): e25096.
37. Wu G, Liu B, Zhang Y, Li J, et al,. Preclinical characterization of GLS4, an inhibitor of hepatitis B virus core particle assembly. Antimicrob Agents Chemother 2013; 57: 5344-5354.
38. Zoulim F, Seeger C,. Reverse transcription in hepatitis B viruses is primed by a tyrosine residue of the polymerase. J Virol 1994; 68: 6-13.
39. Weber M, Bronsema V, Bartos H, Bosserhoff A, Bartenschlager R, Schaller H,. Hepadnavirus P protein utilizes a tyrosine residue in the TP domain to prime reverse transcription. J Virol 1994; 68: 2994-2999.
40. Nassal M, Schaller H,. Hepatitis B virus replication-an update. J Viral Hepat 1996; 3: 217-226.
41. Karayiannis P,. Direct acting antivirals for the treatment of chronic viral hepatitis. Scientifica (Cairo) 2012; 2012: 478631.
42. Hu Y, Cheng X, Cao F, Huang A, Tavis JE,. β-Thujaplicinol inhibits hepatitis B virus replication by blocking the viral ribonuclease H activity. Antiviral Res 2013; 99: 221-229.
43. Budihas SR, Gorshkova I, Gaidamakov S, et al,. Selective inhibition of HIV-1 reverse transcriptase-associated ribonuclease H activity by hydroxylated tropolones. Nucleic Acids Res 2005; 33: 1249-1256.
44. Beilhartz GL, Wendeler M, Baichoo N, Rausch J, Le Grice S, Götte M,. HIV-1 reverse transcriptase can simultaneously engage its DNA/RNA substrate at both DNA polymerase and RNase H active sites: implications for RNase H inhibition. J Mol Biol 2009; 388: 462-474.
45. Gerelsaikhan T, Tavis JE, Bruss V,. Hepatitis B virus nucleocapsid envelopment does not occur without genomic DNA synthesis. J Virol 1996; 70: 4269-4272.
46. http://www.medhelp.org/posts/Hepatitis-B/New-REP-9AC-Clinical-Trial-/show/2034553 (accessed 02 June 2014).
47. Pol S, Nalpas B, Driss F, et al,. Efficacy and limitations of a specific immunotherapy in chronic hepatitis B. J Hepatol 2001; 34: 917-921.
48. Heathcote J, McHutchison J, Lee S, et al,. A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. The CY1899 T Cell Vaccine Study Group. Hepatology 1999; 30: 531-536.
49. Xu DZ, Wang XY, Shen XL, et al,. YIC Efficacy Trial Study Team. Results of a phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: experiences and findings. J Hepatol 2013; 59: 450-456.
50. Buchmann P, Dembek C, Kuklick L, et al,. A novel therapeutic hepatitis B vaccine induces cellular and humoral immune responses and breaks tolerance in hepatitis B virus (HBV) transgenic mice. Vaccine 2013; 31: 1197-1203.
51. Jager C, Ringelhan M, Dembek C, Backes S, et al,. Therapeutic vaccination for chronic hepatitis B (CHB) using heterologous protein prime/vector boost vaccination scheme. J Hepatol 2013; 58 (Suppl. 1): S305 (Abstract 752).
52. Mahtab MA, Akbar F, Uddin H, Rahman S, et al,. A phase III clinical trial with a nasal vaccine containing both HBsAg and HBcAg in patients with chronic hepatitis B. J Hepatol 2013; 58 (Suppl. 1): S309 (Abstract 760).
53. Gaggar A, Coeshott C, Subramanian M, McHutchison JG, Apelian D,. Safety, tolerability and immunogenicity of GS-4774, an HBV-specific therapeutic vaccine, in healthy volunteers. Hepatology 2013; 58 (Suppl. 1): 656A (Abstract 938).
54. Malanchere-Bres E, Payette PJ, Mancini M, Tiollais P, Davis HL, Michel ML,. CpG oligodeoxynucleotides with hepatitis B surface antigen (HBsAg) for vaccination in HBsAg-transgenic mice. J Virol 2001; 75: 6482-6491.
55. Davis HL, Suparto II, Weeratna RR, et al,. CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans. Vaccine 2000; 18: 1920-1924.
56. Ren GL, Huang GY, Zheng H, et al,. Changes in innate and permissive immune responses after HBV transgenic mouse vaccination and llong-term-siRNA treatment. PLoS One 2013; 8: e57525.
57. Farag MM, Tedjokusumo R, Flechtenmacher C, et al,. Immune tolerance against HBV can be overcome in HBV transgenic mice by immunization with dendritic cells pulsed by HBVsvp. Vaccine 2012; 30: 6034-6039.
58. Wu FB, Yang YJ, Zhang LY, et al,. A clinical trial on anti -HBV-DC vaccine combined with lamivudine and thymosin -a1 in the HBeAg positive patients of chronic hepatitis B virus infection. J Hepatol 2013; 58 (Suppl. 1): S318 (Abstract 781).
59. Martinet J, Leroy V, Dufeu-Duchesne T, et al,. Plasmacytoid dendritic cells induce efficient stimulation of antiviral immunity in the context of chronic hepatitis B virus infection. Hepatology 2012; 56: 1706-1718.
60. Akbar SM, Chen S, Al-Mahtab M, Abe M, Hiasa Y, Onji M,. Strong and multi-antigen specific immunity by hepatitis B core antigen (HBcAg)-based vaccines in a murine model of chronic hepatitis B: HBcAg is a candidate for a therapeutic vaccine against hepatitis B virus. Antiviral Res 2012; 96: 59-64.
61. Cova L,. Advances and challenges in the development of therapeutic DNA vaccines against hepatitis B virus infection. Curr Gene Ther 2014; 14: 149-60.
62. Liu J, Zhang E, Ma Z, et al,. Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection. PLoS Pathog 2014; 10: e1003856.
63. Yang FQ, Yu YY, Wang GQ, et al,. A pilot randomized controlled trial of dual-plasmid HBV DNA vaccine mediated by in vivo electroporation in chronic hepatitis B patients under lamivudine chemotherapy. J Viral Hepat 2012; 19: 581-593.
64. Godon O, Fontaine H, Kahi S, et al,. Immunological and antiviral responses after therapeutic DNA immunization in chronic hepatitis B patients efficiently treated by analogues. Mol Ther 2014; 22: 675-684.
65. Yoon SK, Seo YB, Im SJ, et al,. Safety and immunogenicity of therapeutic DNA vaccine with antiviral drug in chronic HBV patients and its immunogenicity in mice. Liver Int 2014; Mar 13. doi: 10.1111/liv.12530. [Epub ahead of print].
66. Kosinska AD, Zhang E, Johrden L, et al,. Combination of DNA prime-adenovirus boost immunization with entecavir elicits sustained control of chronic hepatitis B in the woodchuck model. PLoS Pathog 2013; 9: e1003391.
67. Cavenaugh JS, Awi D, Mendy M, Hill AV, Whittle H, McConkey SJ,. Partially randomized, non-blinded trial of DNA and MVA therapeutic vaccines based on hepatitis B virus surface protein for chronic HBV infection. PLoS One 2011; 6: e14626.
68. Lanford RE, Guerra B, Chavez D, et al,. GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees. Gastroenterology 2013; 144: 1508-1517.